Sobi files oral Orfadin in Europe
This article was originally published in Scrip
An application by Swedish Orphan Biovitrum (Sobi) for an oral suspension of Orfadin (nitisinone) has been accepted by the European Medicines Agency (EMA). The new dosage form is aimed at making the administration of Orfadin, currently formulated as a hard capsule, easier and more accurate.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.